TIAA Trust National Association Has $4.69 Million Position in Colgate-Palmolive (NYSE:CL)

TIAA Trust National Association trimmed its position in Colgate-Palmolive (NYSE:CLFree Report) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,861 shares of the company’s stock after selling 1,242 shares during the quarter. TIAA Trust National Association’s holdings in Colgate-Palmolive were worth $4,692,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Welch Group LLC grew its holdings in Colgate-Palmolive by 2.1% in the 4th quarter. Welch Group LLC now owns 631,892 shares of the company’s stock valued at $50,368,000 after buying an additional 12,755 shares in the last quarter. First Citizens Bank & Trust Co. grew its holdings in Colgate-Palmolive by 15.6% in the 4th quarter. First Citizens Bank & Trust Co. now owns 7,491 shares of the company’s stock valued at $597,000 after buying an additional 1,010 shares in the last quarter. Essex Savings Bank grew its holdings in Colgate-Palmolive by 15.7% in the 4th quarter. Essex Savings Bank now owns 13,082 shares of the company’s stock valued at $1,043,000 after buying an additional 1,772 shares in the last quarter. Veracity Capital LLC grew its holdings in shares of Colgate-Palmolive by 6.1% during the 4th quarter. Veracity Capital LLC now owns 7,618 shares of the company’s stock worth $607,000 after purchasing an additional 435 shares in the last quarter. Finally, Bridge Creek Capital Management LLC grew its holdings in shares of Colgate-Palmolive by 0.5% during the 4th quarter. Bridge Creek Capital Management LLC now owns 59,429 shares of the company’s stock worth $4,737,000 after purchasing an additional 310 shares in the last quarter. 80.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Colgate-Palmolive news, CEO Noel R. Wallace sold 29,772 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $84.06, for a total value of $2,502,634.32. Following the completion of the sale, the chief executive officer now owns 301,343 shares of the company’s stock, valued at $25,330,892.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Colgate-Palmolive news, CEO Noel R. Wallace sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $83.15, for a total value of $4,157,500.00. Following the completion of the sale, the chief executive officer now owns 274,179 shares of the company’s stock, valued at $22,797,983.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Noel R. Wallace sold 29,772 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $84.06, for a total value of $2,502,634.32. Following the completion of the sale, the chief executive officer now directly owns 301,343 shares of the company’s stock, valued at approximately $25,330,892.58. The disclosure for this sale can be found here. Insiders sold 232,371 shares of company stock valued at $19,505,099 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Colgate-Palmolive Trading Up 0.0 %

NYSE CL opened at $89.10 on Wednesday. The business has a 50 day simple moving average of $86.08 and a 200 day simple moving average of $79.45. Colgate-Palmolive has a one year low of $67.62 and a one year high of $90.37. The stock has a market capitalization of $73.24 billion, a P/E ratio of 32.05, a P/E/G ratio of 3.39 and a beta of 0.42. The company has a debt-to-equity ratio of 8.59, a current ratio of 1.11 and a quick ratio of 0.71.

Colgate-Palmolive (NYSE:CLGet Free Report) last released its earnings results on Friday, January 26th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.85 by $0.02. Colgate-Palmolive had a return on equity of 509.75% and a net margin of 11.82%. The business had revenue of $4.95 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter last year, the firm posted $0.77 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. Research analysts expect that Colgate-Palmolive will post 3.49 earnings per share for the current year.

Colgate-Palmolive Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 22nd will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, April 19th. This represents a $2.00 annualized dividend and a yield of 2.24%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.48. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 69.06%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on CL shares. TheStreet raised Colgate-Palmolive from a “c+” rating to a “b+” rating in a report on Friday, January 26th. UBS Group increased their target price on Colgate-Palmolive from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, January 29th. The Goldman Sachs Group initiated coverage on Colgate-Palmolive in a research report on Friday, March 1st. They issued a “buy” rating and a $93.00 target price for the company. Morgan Stanley increased their target price on Colgate-Palmolive from $85.00 to $93.00 and gave the company an “overweight” rating in a research report on Monday, January 29th. Finally, StockNews.com downgraded Colgate-Palmolive from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $87.31.

View Our Latest Analysis on Colgate-Palmolive

About Colgate-Palmolive

(Free Report)

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

Recommended Stories

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CLFree Report).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.